Cargando…
Pharmacological targeting of Tripartite Motif Containing 24 for the treatment of glioblastoma
Glioblastoma (GBM) is the most aggressive brain tumor of the central nervous system. Recent studies have reported the crucial functions of Tripartite Motif Containing 24 (TRIM24) in promoting cancer progression of GBM. However, it remains unclear if TRIM24 is an attractive druggable target for thera...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662887/ https://www.ncbi.nlm.nih.gov/pubmed/34886858 http://dx.doi.org/10.1186/s12967-021-03158-w |
_version_ | 1784613530863927296 |
---|---|
author | Han, Mingzhi Sun, Yanfei |
author_facet | Han, Mingzhi Sun, Yanfei |
author_sort | Han, Mingzhi |
collection | PubMed |
description | Glioblastoma (GBM) is the most aggressive brain tumor of the central nervous system. Recent studies have reported the crucial functions of Tripartite Motif Containing 24 (TRIM24) in promoting cancer progression of GBM. However, it remains unclear if TRIM24 is an attractive druggable target for therapeutic intervention in GBM. We therefore performed a series of experiments, aiming to verify whether specific TRIM24 inhibition suppresses GBM malignant functions using dTRIM24 and IACS-9571, two novel selective TRIM24 antagonists. Our data showed that TRIM24 inhibitors serve as effective agents for inhibiting cell propagation and invasion of several patient-derived GBM stem cells (GSCs), and these effects are mediated partially through suppression of the TRIM24-SOX2 axis. This study provides novel insight into the TRIM24-based druggable dependencies, important for developing effective therapeutic strategies for brain tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-03158-w. |
format | Online Article Text |
id | pubmed-8662887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86628872021-12-13 Pharmacological targeting of Tripartite Motif Containing 24 for the treatment of glioblastoma Han, Mingzhi Sun, Yanfei J Transl Med Letter to the Editor Glioblastoma (GBM) is the most aggressive brain tumor of the central nervous system. Recent studies have reported the crucial functions of Tripartite Motif Containing 24 (TRIM24) in promoting cancer progression of GBM. However, it remains unclear if TRIM24 is an attractive druggable target for therapeutic intervention in GBM. We therefore performed a series of experiments, aiming to verify whether specific TRIM24 inhibition suppresses GBM malignant functions using dTRIM24 and IACS-9571, two novel selective TRIM24 antagonists. Our data showed that TRIM24 inhibitors serve as effective agents for inhibiting cell propagation and invasion of several patient-derived GBM stem cells (GSCs), and these effects are mediated partially through suppression of the TRIM24-SOX2 axis. This study provides novel insight into the TRIM24-based druggable dependencies, important for developing effective therapeutic strategies for brain tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-03158-w. BioMed Central 2021-12-09 /pmc/articles/PMC8662887/ /pubmed/34886858 http://dx.doi.org/10.1186/s12967-021-03158-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Letter to the Editor Han, Mingzhi Sun, Yanfei Pharmacological targeting of Tripartite Motif Containing 24 for the treatment of glioblastoma |
title | Pharmacological targeting of Tripartite Motif Containing 24 for the treatment of glioblastoma |
title_full | Pharmacological targeting of Tripartite Motif Containing 24 for the treatment of glioblastoma |
title_fullStr | Pharmacological targeting of Tripartite Motif Containing 24 for the treatment of glioblastoma |
title_full_unstemmed | Pharmacological targeting of Tripartite Motif Containing 24 for the treatment of glioblastoma |
title_short | Pharmacological targeting of Tripartite Motif Containing 24 for the treatment of glioblastoma |
title_sort | pharmacological targeting of tripartite motif containing 24 for the treatment of glioblastoma |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662887/ https://www.ncbi.nlm.nih.gov/pubmed/34886858 http://dx.doi.org/10.1186/s12967-021-03158-w |
work_keys_str_mv | AT hanmingzhi pharmacologicaltargetingoftripartitemotifcontaining24forthetreatmentofglioblastoma AT sunyanfei pharmacologicaltargetingoftripartitemotifcontaining24forthetreatmentofglioblastoma |